Risk of developing active tuberculosis following tuberculosis screening and preventive therapy for Tibetan refugee children and adolescents in India: An impact assessment.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
01 2021
Historique:
received: 15 07 2020
accepted: 29 12 2020
revised: 02 02 2021
pubmed: 20 1 2021
medline: 7 5 2021
entrez: 19 1 2021
Statut: epublish

Résumé

Tuberculosis (TB) rates among Tibetan refugee children and adolescents attending boarding schools in India are extremely high. We undertook a comprehensive case finding and TB preventive treatment (TPT) program in 7 schools in the Zero TB Kids project. We aimed to measure the TB infection and disease burden and investigate the risk of TB disease in children and adults who did and did not receive TPT in the schools. A mobile team annually screened children and staff for TB at the 7 boarding schools in Himachal Pradesh, India, using symptom criteria, radiography, molecular diagnostics, and tuberculin skin tests. TB infection (TBI) was treated with short-course regimens of isoniazid and rifampin or rifampin. TB disease was treated according to Tibetan and Indian guidelines. Between April 2017 and December 2019, 6,582 schoolchildren (median age 14 [IQR 11-16] years) and 807 staff (median age 40 [IQR 33-48] years) were enrolled. Fifty-one percent of the students and 58% of the staff were females. Over 13,161 person-years of follow-up in schoolchildren (median follow-up 2.3 years) and 1,800 person-years of follow-up in staff (median follow-up 2.5 years), 69 TB episodes occurred in schoolchildren and 4 TB episodes occurred in staff, yielding annual incidence rates of 524/100,000 (95% CI 414-663/100,000) person-years and 256/100,000 (95% CI 96-683/100,000) person-years, respectively. Of 1,412 schoolchildren diagnosed with TBI, 1,192 received TPT. Schoolchildren who received TPT had 79% lower risk of TB disease (adjusted hazard ratio [aHR] 0.21; 95% CI 0.07-0.69; p = 0.010) compared to non-recipients, the primary study outcome. Protection was greater in recent contacts (aHR 0.07; 95% CI 0.01-0.42; p = 0.004), the secondary study outcome. The prevalence of recent contacts was 28% (1,843/6,582). Two different TPT regimens were used (3HR and 4R), and both were apparently effective. No staff receiving TPT developed TB. Overall, between 2017 and 2019, TB disease incidence decreased by 87%, from 837/100,000 (95% CI 604-1,129/100,000) person-years to 110/100,000 (95% CI 36-255/100,000) person-years (p < 0.001), and TBI prevalence decreased by 42% from 19% (95% CI 18%-20%) to 11% (95% CI 10%-12%) (p < 0.001). A limitation of our study is that TB incidence could be influenced by secular trends during the study period. In this study, following implementation of a school-wide TB screening and preventive treatment program, we observed a significant reduction in the burden of TB disease and TBI in children and adolescents. The benefit of TPT was particularly marked for recent TB contacts. This initiative may serve as a model for TB detection and prevention in children and adolescents in other communities affected by TB.

Sections du résumé

BACKGROUND
Tuberculosis (TB) rates among Tibetan refugee children and adolescents attending boarding schools in India are extremely high. We undertook a comprehensive case finding and TB preventive treatment (TPT) program in 7 schools in the Zero TB Kids project. We aimed to measure the TB infection and disease burden and investigate the risk of TB disease in children and adults who did and did not receive TPT in the schools.
METHODS AND FINDINGS
A mobile team annually screened children and staff for TB at the 7 boarding schools in Himachal Pradesh, India, using symptom criteria, radiography, molecular diagnostics, and tuberculin skin tests. TB infection (TBI) was treated with short-course regimens of isoniazid and rifampin or rifampin. TB disease was treated according to Tibetan and Indian guidelines. Between April 2017 and December 2019, 6,582 schoolchildren (median age 14 [IQR 11-16] years) and 807 staff (median age 40 [IQR 33-48] years) were enrolled. Fifty-one percent of the students and 58% of the staff were females. Over 13,161 person-years of follow-up in schoolchildren (median follow-up 2.3 years) and 1,800 person-years of follow-up in staff (median follow-up 2.5 years), 69 TB episodes occurred in schoolchildren and 4 TB episodes occurred in staff, yielding annual incidence rates of 524/100,000 (95% CI 414-663/100,000) person-years and 256/100,000 (95% CI 96-683/100,000) person-years, respectively. Of 1,412 schoolchildren diagnosed with TBI, 1,192 received TPT. Schoolchildren who received TPT had 79% lower risk of TB disease (adjusted hazard ratio [aHR] 0.21; 95% CI 0.07-0.69; p = 0.010) compared to non-recipients, the primary study outcome. Protection was greater in recent contacts (aHR 0.07; 95% CI 0.01-0.42; p = 0.004), the secondary study outcome. The prevalence of recent contacts was 28% (1,843/6,582). Two different TPT regimens were used (3HR and 4R), and both were apparently effective. No staff receiving TPT developed TB. Overall, between 2017 and 2019, TB disease incidence decreased by 87%, from 837/100,000 (95% CI 604-1,129/100,000) person-years to 110/100,000 (95% CI 36-255/100,000) person-years (p < 0.001), and TBI prevalence decreased by 42% from 19% (95% CI 18%-20%) to 11% (95% CI 10%-12%) (p < 0.001). A limitation of our study is that TB incidence could be influenced by secular trends during the study period.
CONCLUSIONS
In this study, following implementation of a school-wide TB screening and preventive treatment program, we observed a significant reduction in the burden of TB disease and TBI in children and adolescents. The benefit of TPT was particularly marked for recent TB contacts. This initiative may serve as a model for TB detection and prevention in children and adolescents in other communities affected by TB.

Identifiants

pubmed: 33465063
doi: 10.1371/journal.pmed.1003502
pii: PMEDICINE-D-20-03413
pmc: PMC7853467
doi:

Substances chimiques

Antitubercular Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003502

Subventions

Organisme : NIAID NIH HHS
ID : K01 AI148583
Pays : United States

Déclaration de conflit d'intérêts

I have read the journal’s policy and the authors of this manuscript have the following competing interests: Spouse of RC owns stock in Merck. RC has received consulting fees from Sanofi. Other authors have declared that no competing interests exist.

Références

Clin Infect Dis. 2015 Feb 15;60(4):639-45
pubmed: 25365974
AIDS. 2007 Jul 11;21(11):1441-8
pubmed: 17589190
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
Int J Tuberc Lung Dis. 2005 Sep;9(9):1018-26
pubmed: 16158895
Eur Respir J. 2018 Feb 21;51(2):
pubmed: 29467206
Eur Respir J. 2016 Oct;48(4):1227-1230
pubmed: 27390274
Lancet Glob Health. 2017 Sep;5(9):e898-e906
pubmed: 28807188
Am Rev Respir Dis. 1962 Dec;86:810-22
pubmed: 14022524
Am Rev Respir Dis. 1979 May;119(5):827-30
pubmed: 453704
N Engl J Med. 2014 Jan 23;370(4):301-10
pubmed: 24450889
Lancet Glob Health. 2014 Aug;2(8):e453-9
pubmed: 25103518
Clin Infect Dis. 2019 Aug 16;69(5):760-768
pubmed: 30462191
Int J Epidemiol. 1973 Summer;2(2):153-60
pubmed: 4204799
Bull World Health Organ. 1965;33(3):419-33
pubmed: 5321762
Int J Tuberc Lung Dis. 2014 Jun;18(6):655-62
pubmed: 24903934
N Engl J Med. 2019 Oct 3;381(14):1347-1357
pubmed: 31577876
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006418
pubmed: 19160285
Am Rev Respir Dis. 1967 Jun;95(6):935-43
pubmed: 6026165
J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):552-8
pubmed: 24853308
Lancet Infect Dis. 2017 Mar;17(3):285-295
pubmed: 27964822
BMC Infect Dis. 2014 Feb 20;14:91
pubmed: 24555539
Annu Rev Public Health. 2013;34:271-86
pubmed: 23244049
Am J Respir Crit Care Med. 2015 May 15;191(10):1202-3
pubmed: 25978574
N Engl J Med. 1961 Oct 12;265:713-21
pubmed: 14476667
Emerg Infect Dis. 2016 Mar;22(3):463-8
pubmed: 26889728

Auteurs

Kunchok Dorjee (K)

Center for TB Research, Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.

Sonam Topgyal (S)

Division of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.

Tenzin Tsewang (T)

Division of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.

Tenzin Tsundue (T)

Division of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.

Tenzin Namdon (T)

Division of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.

Elizabeth Bonomo (E)

Center for TB Research, Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.

Caroline Kensler (C)

Center for TB Research, Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.

Dekyi Lhadon (D)

Division of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.

Tsering Choetso (T)

Division of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.

Tenzin Nangsel (T)

Division of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.

Tsering Dolkar (T)

Division of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.

Thupten Tsekyi (T)

Division of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.

Chungdak Dorjee (C)

Tibetan Children's Village School, Dharamsala, India.

Dawa Phunkyi (D)

Division of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.

Tsetan D Sadutshang (TD)

Division of Tuberculosis, Delek Hospital, Department of Health, Central Tibetan Administration, Dharamsala, India.

Zorba Paster (Z)

Department of Family Medicine, University of Wisconsin, Madison, Wisconsin, United States of America.

Richard E Chaisson (RE)

Center for TB Research, Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH